文献速递肿瘤 PET/CT放射性药物与辐射防护

健康人与肺纤维化患者肺内整合素αvβ6的[18F]FB-A20FMDV2 PET临床定量研究

Clinical quantification of the integrin αvβ6 by [18F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study).
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-12-09

本研究用αvβ6选择性PET配体[18F]FB-A20FMDV2对健康人和肺纤维化患者进行PET/CT显像,定量肺内αvβ6表达。共纳入15例(6例健康、7例IPF、2例CTD相关PF),PF患者肺内VT和SUV均高于健康人,且摄取增高主要局限于纤维化区域,测量在2周间隔可重复,配体安全耐受。

要点

  • PF患者肺内[18F]FB-A20FMDV2的VT和SUV均高于健康人
  • 摄取增高主要局限于高分辨率CT所示的纤维化区域
  • 该PET测量在2周间隔可重复,配体安全且耐受良好

核心结论

  • 肺纤维化患者肺内[18F]FB-A20FMDV2摄取较健康人明显增高,该摄取反映整合素αvβ6表达。

研究设计与样本

  • 在健康受试者和肺纤维化患者中行[18F]FB-A20FMDV2 PET/CT显像,用SUV和VT定量αvβ6表达。
  • 共纳入15例参与者,包括6例健康、7例特发性肺纤维化(IPF)和2例结缔组织病相关肺纤维化(CTD-PF)。
  • 对肺纤维化患者进行αvβ6表达与高分辨率CT纤维化分布关系的定性评估。

主要发现

  • 健康人VT几何均值(95%CI)为0.88(0.60,1.29)mL/cm3,IPF患者为1.40(1.22,1.61)mL/cm3。
  • 健康人SUV几何均值(95%CI)为0.54(0.36,0.81)g/mL,IPF患者为1.03(0.86,1.22)g/mL。
  • IPF/健康VT比值几何均值(比值95%CI)为1.59(1.09,2.32),比值>1的概率为0.988。
  • IPF/健康SUV比值几何均值(比值95%CI)为1.91(1.27,2.87),比值>1的概率为0.996。
  • 肺纤维化患者中[18F]FB-A20FMDV2摄取增高主要局限于纤维化区域。

关键数值与推荐

  • IPF患者肺内[18F]FB-A20FMDV2的VT几何均值为1.40(1.22,1.61)mL/cm3,健康人为0.88(0.60,1.29)mL/cm3。
  • IPF患者肺内SUV几何均值为1.03(0.86,1.22)g/mL,健康人为0.54(0.36,0.81)g/mL。
  • IPF/健康VT比值几何均值为1.59(1.09,2.32),SUV比值几何均值为1.91(1.27,2.87)。

临床怎么用

  • 该PET显像可用于定量肺内整合素αvβ6表达,辅助评估肺纤维化患者的靶点表达水平。

局限性

  • 样本量小,共纳入15例参与者,其中CTD相关PF仅2例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The RGD-integrin, αvβ6, plays a role in the pathogenesis of pulmonary fibrosis through activation of transforming growth factor beta (TGFβ). This study sought to quantify expression of αvβ6 in the lungs of healthy humans and subjects with pulmonary fibrosis using the αvβ6-selective [18F]FB-A20FMDV2 PET ligand. METHODS: [18F]FB-A20FMDV2 PET/CT scans were performed in healthy subjects and those with fibrotic lung disease. Standard uptake values (SUV) and volume of distribution (VT) were used to quantify αvβ6 expression. In subjects with fibrotic lung disease, qualitative assessment of the relationship between αvβ6 expression and the distribution of fibrosis on high resolution computed tomography was conducted. RESULTS: A total of 15 participants (6 healthy, 7 with idiopathic pulmonary fibrosis (IPF) and 2 with connective tissue disease (CTD) associated PF) were enrolled. VT and SUV of [18F]FB-A20FMDV2 were increased in the lungs of subjects with pulmonary fibrosis (PF) compared with healthy subjects. Geometric mean VT (95% CI) was 0.88 (0.60, 1.29) mL/cm3 for healthy subjects, and 1.40 (1.22, 1.61) mL/cm3 for subjects with IPF; and SUV was 0.54 (0.36, 0.81) g/mL for healthy subjects and 1.03 (0.86, 1.22) g/mL for subjects with IPF. The IPF/healthy VT ratio (geometric mean, (95% CI of ratio)) was 1.59 (1.09, 2.32) (probability ratio > 1 = 0.988)) and the SUV ratio was 1.91 (1.27, 2.87) (probability ratio > 1 = 0.996). Increased uptake of [18F]FB-A20FMDV2 in PF was predominantly confined to fibrotic areas. [18F]FB-A20FMDV2 measurements were reproducible at an interval of 2 weeks. [18F]FB-A20FMDV2 was safe and well tolerated. CONCLUSIONS: Lung uptake of [18F]FB-A20FMDV2, a measure of expression of the integrin αvβ6, was markedly increased in subjects with PF compared with healthy subjects.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Lukey PT, Coello C, Gunn R, et al. Clinical quantification of the integrin αvβ6 by [18F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study). Eur J Nucl Med Mol Imaging. 2019. PMID: 31814068. doi:10.1007/s00259-019-04586-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。